UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 1-U
CURRENT REPORT PURSUANT TO REGULATION A
Date of Report (Date of earliest event reported): March 6, 2024
Emerald Health Pharmaceuticals Inc.
(Exact name of issuer as specified in its charter)
Delaware
State or other jurisdiction of incorporation or organization
82-0669961
(I.R.S. Employer Identification No.)
5910 Pacific Center Blvd., Suite 320, San Diego, CA 92121
(Full mailing address of principal executive offices)
(858) 352 - 0622
(Issuer’s telephone number, including area code)
Common stock, par value $0.0001
(Title of each class of securities issued pursuant to Regulation A)
Item 7. Departure of Certain Officers
Effective March 6th, 2024, Mr. Jospeh A. Lugo resigned as the Company’s secretary and interim principal executive officer.
1
SIGNATURES
Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| EMERALD HEALTH PHARMACEUTICALS INC., | ||
| a Delaware corporation | ||
| By: | /s/ Robert E. Hawk | |
| Name: | Robert E. Hawk | |
| Title: | Authorized Signatory | |
Date: March 18, 2024
2
